STATUS: The meeting will be open to the public.

MATTERS TO BE CONSIDERED:

Open Session

- 1. Announcement of Notation Votes, and
- 2. FY 2007 Budget Allocations for the State and Local Program.

Note: In accordance with the Sunshine Act, the meeting will be open to public observation of the Commission's deliberations and voting. (In addition to publishing notices on EEOC Commission meetings in the Federal Register, the Commission also provides a recorded announcement a full week in advance on future Commission sessions.)

Please telephone (202) 663–7100 (voice) and (202) 663–4074 (TTY) at any time for information on these meetings. The EEOC provides sign language interpretation at Commission meetings for the hearing impaired. Requests for other reasonable accommodations may be made by using the voice and TTY numbers listed above.

FOR FURTHER INFORMATION CONTACT:

Stephen Llewellyn, Acting Executive Officer, on (202) 663–4070.

Dated: March 28, 2007.

Stephen Llewellyn,

Acting Executive Officer, Executive Secretariat.

[FR Doc. 07–1607 Filed 3–28–07; 12:36 pm] BILLING CODE 6570–06–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Meeting: Vaccine Safety Evaluation: Post-Marketing Surveillance

AGENCY: Department of Health and Human Services, Office of the Secretary. **ACTION:** Notice.

SUMMARY: The National Vaccine
Program Office is hereby giving notice
that, in conjunction with the National
Institutes of Health, the Food and Drug
Administration, the Centers for Disease
Control and Prevention, and the Health
Resources and Services Administration,
is hosting a 2-day meeting titled:
Vaccine Safety Evaluation: Postmarketing Surveillance. The meeting is
open to the public.

DATES: The meeting will be held on April 10, 2007, from 9 a.m. to 6 p.m., and on April 11, 2007, from 9 a.m. to 5 p.m.

ADDRESS: National Institutes of Health, 9000 Rockville Pike, Natcher Auditorium—Building 45, Bethesda, Maryland 20892.

FOR FURTHER INFORMATION CONTACT: Dr. Kenneth Bart, National Vaccine Program Office, Department of Health and Human Services, Room 443–H, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201; (202) 690–5566, Kenneth.bart@hhs.gov.

SUPPLEMENTARY INFORMATION: The principal theme of the meeting is, "What should an ideal post-licensure vaccine safety system be?" As part of a continuing effort to maximize the safety of vaccines, the meeting will review what the United States is currently doing in post-marketing surveillance of vaccine safety and their strengths and weaknesses. In addition, with the participation of international experts, we expect to learn about what has worked in other countries, new methodologies that are being experimented with, and areas where new research could be directed.

Public attendance at the meeting is limited to space available. Individuals must provide a photo ID for entry onto the National Institutes of Health (NIH) campus. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the designated contact person. Members of the public will have the opportunity to provide comments at the meeting. Public comment will be limited to five minutes per speaker. Any members of the public who wish to have printed material distributed to meeting attendees should submit materials to the contact person listed above prior to close of business April 2, 2007. Additionally, should you wish to make a brief presentation, please contact Dr. Kenneth Bart using the contact information provided above.

Due to security measures at the NIH campus, pre-registration will greatly ease entrance onto the campus. Any individual who wish to attend the meeting should submit that request via e-mail to *nvpo*-

meetings@constellagroup.com. Please note that registration must be completed by close of business on April 2, 2007.

Additional information, including a draft agenda, can be found at: http://www.hhs.gov/nvpo.

Dated: March 27, 2007.

Bruce Gellin,

Director, National Vaccine Program Office. [FR Doc. E7–5917 Filed 3–29–07; 8:45 am] BILLING CODE 4150–44–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

The Health Department Subcommittee (HDS) of the Board of Scientific Counselors (BSC), Centers for Disease Control and Prevention (CDC), National Center for Environmental Health (NCEH)/Agency for Toxic Substances and Disease Registry (ATSDR): Teleconference Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the CDC, NCEH/ ATSDR announces the following teleconference meeting of the aforementioned subcommittee:

Time and Date: 12:30 p.m.–2 p.m., April 23, 2007, Eastern Daylight Saving Time.

Place: Century Center, 1825 Century Boulevard, Atlanta, Georgia 30345.

Status: Open to the public; teleconference access limited only by availability of telephone ports.

Purpose: Under the charge of the BSC, NCEH/ATSDR, the HDS will provide the BSC, NCEH/ATSDR with advice and recommendations on local and State health department issues and concerns that pertain to the mandates and mission of NCEH/ATSDR.

Matters to be Discussed: The meeting will include a review of the agenda; approval of minutes from the last conference call; a review "matrix" for recommendations of workforce issues and science issues; a briefing on issues important to schools; pubic comment and the next steps for the HDS.

Items are subject to change as priorities dictate.

SUPPLEMENTARY INFORMATION: To participate in this teleconference meeting, please dial 877/315–6535 and enter conference code 383520. The public comment period is scheduled from 1:20 p.m.–1:30 p.m. Eastern Daylight Saving Time.

FOR FURTHER INFORMATION CONTACT:

Shirley D. Little, Committee Management Specialist, NCEH/ATSDR, CDC, 1600 Clifton Road, Mail Stop E–28, Atlanta, GA 30303; telephone 404/498–0615; fax 404/498–0059; e-mail: slittle@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.